KPV — compound monograph
C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone. Unapproved, research supply. The Institute assesses 2 outcomes for this compound and grades the strongest at very low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- KPV
- Compound class
- C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone
- Assessment series
- Repair and regeneration
- Synonyms and codes
- Lys-Pro-Val · alpha-MSH(11-13) · tripeptide KPV
- Route as evaluated
- Oral, topical or subcutaneous in preclinical studies
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 67727-97-3
- Molecular formula
- C16H30N4O4
- Average mass
- 342.44
- Monoisotopic mass
- 342.23
- ATC classification
- not assigned
§1.3Sequence and structural notes
The C-terminal tripeptide of alpha-melanocyte-stimulating hormone. It retains the anti-inflammatory activity of the parent hormone while lacking the melanocortin receptor-mediated pigmentary and cardiovascular effects, which is the basis of therapeutic interest.
§1.4Assessment status
The Institute assesses KPV across 2 indications and grades the strongest of them at very low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.
Table 1. Assessed outcomes for KPV, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Cutaneous wound healing and tissue repair | No randomised controlled human trial identified | Very low | 0 |
| Inflammatory bowel disease and mucosal barrier disorders | No randomised controlled human trial identified | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.